NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

著者: Daniel A. Pollyea, Dale L. Bixby, Alexander E. Perl, Vijaya Raj Bhatt, Jessica K. Altman, Frederick R. Appelbaum, Marcos de Lima, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Meagan A. Jacoby, Jeffrey E. Lancet, Gabriel N. Mannis, Guido Marcucci, Michael G. Martin, Alice S. Mims, Jadee Neff, Reza Nejati, Rebecca L. Olin, Mary‐Elizabeth M. Percival, Thomas Prébet, Amanda Przespolewski, Dinesh S. Rao, Farhad Ravandi‐Kashani, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Kendra Sweet, Pankit Vachhani, Matthew J. Wieduwilt, Kristina M. Gregory, Ndiya Ogba, Martin S. Tallman - Journal of the National Comprehensive Cancer Network 2021 被引用: 326

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States.1 The NCCN Guidelines Panel for AML convenes annually to update recommendations for the diagnosis and treatment of AML in adults. These recommendations are based on a review of recently published clinical trials that have led to significant improvements in treatment or have yielded new information regarding biologic factors that may have prognostic importance. These NCCN Guidelines Insights summarize the panel's most recent recommendations regarding the monitoring and management of measurable (minimal) residual disease.